Bosch-Barrera J; Queralt B; Menendez JA "Targeting STAT3 with silibinin to improve cancer therapeutics." Cancer Treatment Reviews (2017): 61-69. Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA. "EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells." Oncology Reports 38 (2017): 263-270. Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA "Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.." Cell Cycle 16 (2017): 1022-1028. Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A. Menendez "BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells." Oncotarget 8 (2017): 35019-35032. Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R "A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.." Lung Cancer (2017): -. Wehler T; Thomas M; Schumann C; Bosch-Barrera J, Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L "A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.." Lung Cancer (2017): 212-216. Sais E; Menéndez JA; Bosch-Barrera J "The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?." Translational Cancer Research 6 (2017): S201-S204. Ferreira-Padilla G; Ferrández-Antón T; Lolas-Stepke F; Almeida-Cabrera R; Brunet J; Bosch-Barrera J "Ethics competences in the undergraduate medical education curriculum: the Spanish experience.." CMJ: Croatian Medical Journal 57 (2016): 493-503. Cuyàs E; Pérez-Sánchez A; Micol V; Menendez JA; Bosch-Barrera J. "STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.." Cell Cycle (2016): -. Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; De Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA. "Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer." Oncotarget 7 (2016): 82185-82199. de Kock L; Bah I; Brunet J; Druker H; Astigarraga I; Bosch-Barrera J; Soglio DB; Nguyen VH; Malkin D; Priest JR; Foulkes WD. "Somatic DICER1 mutations in adult-onset pulmonary blastoma." European Respiratory Journal (2016): -. Bosch-Barrera J; Sais E; Cañete N; Marruecos J; Cuyàs E; Izquierdo A; Porta R; Haro M; Brunet J; Pedraza S; Menendez JA "Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin." Oncotarget 7 (2016): 32006-32014. Fernández-Arroyo S; Cuyàs E; Bosch-Barrera J; Alarcón T; Joven J; Menendez JA "Activation of the methylation cycle in cells reprogrammed into a stem cell-like state.." Oncoscience 2 (2016): 958-967. Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Vite "BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.." Scientific Reports (2015): -. Bosch-Barrera J; Holguin F; Baldó X; Rubio M; Porta R; Fuentes R; Teixidó C; Ramirez JL; Ferran N; Sebastián F; Rosell R "Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression." Anticancer Research 35 (2015): 4871-4875. Cuyàs, E; Fernández-Arroyo, S; Corominas-Faja, B; Rodríguez-Gallego, E; Bosch-Barrera, J; Martin-Castillo, B; De Llorens, R; Joven, J; Menendez, J.A "Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype." Oncotarget 6 (2015): 12279-12296. Cuyàs, E; Martin-Castillo, B; Corominas-Faja, B; Massaguer, A; Bosch-Barrera, J; Menendez, J.A. "Anti-protozoal and anti-bacterial Antibiotics that inhibit protein synthesis kill Cancer subtypes enriched for stem cell-like properties." Cell Cycle 14 (2015): 3527-3532. Bosch-Barrera J; Briceño García HC; Capella D; De Castro Vila C; Farrés R; Quintanas A; Ramis J; Roca R; Brunet J "Teaching Bioethics to Students of Medicine with Problem-Based Learning (PBL)." Cuadernos de Bioética 26 (2015): 303-309. Bosch-Barrera J; Menendez JA. "Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.." Cancer Treatment Reviews (2015): -. Sauri T; Izquierdo À; Ramió-Torrentà L; Sanchez-Montañez À; Bosch-Barrera J; Porta R "Paraneoplastic Limbic Encephalitis in a Male with Squamous CellCarcinoma of the Lung." Journal Of Clinical Neurology 11 (2015): 87-91. Vidal J; Clavé S; de Muga S; González I; Pijuan L; Gimeno J; Remón J; Reguart N; Viñolas N; Gironés R; Bernet L;, Majem M; Bosch-Barrera J; Porta R; Alonso N; Palmero R; Taus A; Albanell J; Espinet B; Salido M; Arriola E "Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients." Journal of Thoracic Oncology 9 (2014): 1816-1820. Bosch-Barrera J; Sais E; Lorencio C; Porta R; Izquierdo A; Menéndez JA; Brunet J; Sirvent JM; Rosell R "Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma." Lung Cancer 86 (2014): 102-104. Corominas-Faja, B; Cuyàs, E; Gumuzio, J; Bosch-Barrera, J; Leis, O; Martin, A.G; Menendez, J.A "Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells." Oncotarget 5 (2014): 8306-8316. Bosch-Barrera J; Corominas-Faja B; Cuyàs E; Martin-Castillo B; Brunet J; Menendez JA "Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient." Anticancer Research 34 (2014): 4323-4327. Javier A. Menendez; Rosa Quirantes-Piné; Esther Rodríguez-Gallego; Sílvia Cufí; Bruna Corominas-Faja; Elisabet Cuyàs; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Antonio Segura-Carretero; Jorge Joven "Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment." Oncotarget 5 (2014): 2344-2348. Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Menendez JA "Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.." Cell Cycle (2013): -. Alejandro Vazquez-Martin; Sílvia Cufí; Cristina Oliveras-Ferraros; Violeta Zenobia Torres-Garcia; Bruna Corominas-Faja; Elisabet Cuyàs; Rosa Bonavia; Joana Visa; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol "IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.." Scientific Reports (2013): -. Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Bruna Corominas-Faja, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Joaquim Bosch-Barr "Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.." Food and Chemical Toxicology (2013): -. Sílvia Cufí; Rosa Bonavia; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Bruna Corominas-Faja; Elisabet Cuyàs; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Joana Visa; Antonio Segura-Carretero; Jorge Joven; Joaqu "Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.." Scientific Reports (2013): -. Castañon E; Bosch-Barrera J; López I; Collado V; Moreno M; López-Picazo JM; Arbea L; Lozano MD; Calvo A; Gil-Bazo I. "Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy.." Journal Of Translational Medicine 11 (2013): -. Bosch-Barrera J; García-Franco C; Guillén-Grima F; Moreno-Jiménez M; López-Picazo JM; Gúrpide A; Pérez-Gracia JL; Aristu J; Torre W; García-Foncillas J; Gil-Bazo I. "The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.." Clinical and Translational Oncology 14 (2012): 835-841. Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA "Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.." British Journal of Cancer 106 (2012): 1406-1414. Sílvia Cufí; Bruna Corominas-Faja; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Joan Dorca; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Javier A. Menendez "Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts." Oncotarget 4 (2012): 395-398. Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Quirantes R; Segura-Carretero A; Micol V; Joven J; Bosch-Barrera J; Del Barco S; Martin-Castillo B; Vellon L; Menendez JA. "Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205." Cell Cycle 11 (2012): 1235-1246. Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Menendez OJ; Bosch-Barrera J; Martin-Castillo B; Joven J; Menendez JA "Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.." Cell Cycle 11 (2012): 865-870. Cristina Oliveras-Ferraros; Anna Massaguer Vall-Llovera; Alejandro Vazquez-Martin; Dolors Carrion Salip; Bernardo Queralt; Silvia Cufí; Begoña Martin-Castillo; Joaquim Bosch-Barrera; Joan Brunet; Rafael De Llorens; Javier A. "Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.." Oncology Reports 27 (2012): 1887-1892. Bosch-Barrera J; Quer N; Brunet J "Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective.." Clinical Lung Cancer 12 (2011): 335-340. Bosch-Barrera J; Urdiroz J; Centeno C "Visual hallucinations and unusual pain related to hypomagnesemia in an advanced cancer patient." Anales del Sistema Sanitario de Navarra 33 (2010): 319-322. Bosch-Barrera J; Espinós J. "Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report.." International Archives of Medicine 3 (2010): 1-3. Bosch-Barrera J; Espinós J; Gómez-Ibáñez A; Gállego Pérez-Larraya J; Iriarte J "Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.." Clinical and Translational Oncology 11 (2009): 765-767. Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I "Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.." Onkologie 32 (2009): 580-584. Bosch-Barrera J; Arbea L; García-Velloso MJ; Gil-Bazo I; García-Foncillas J; Panizo C "Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.." Cases Journal 2 (2009): 1-5. Bosch-Barrera J; Montero A; López-Picazo JM; García-Foncillas J; Ferrer M; Yuste JR; Gil-Bazo I. "Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer." Lung Cancer 64 (2009): 124-126.
Bosch-Barrera J; Gil-Bazo I. "Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany." Lung Cancer 71 (2011): 244-244.
Isla D; Afonso R; Bosch-Barrera J; Martínez N. "Zoledronic acid in lung cancer with bone metastases: a review.." Expert Review Of Anticancer Therapy 13 (2013): 421-426. Del Barco S; Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Bosch-Barrera J; Joven J; Martin-Castillo B; Menendez JA. "Metformin: multi-faceted protection against cancer.." Oncotarget 2 (2011): 896-917. Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C "Direct antitumour activity of zoledronic acid: preclinical and clinical data." Clinical and Translational Oncology 13 (2011): 148-155. Bosch-Barrera J "Ethical dilemmas in the medical practice in 2010: reflexions around the results of a survey to 10,000 physicians." Cuadernos de Bioética 22 (2011): 113-118. Bosch-Barrera J; Hernández A; Abella LE "Insulin and insulin-like growth factor pathway, a new targeted therapy in oncology." Anales del Sistema Sanitario de Navarra 32 (2009): 413-421. Bosch Barrera, J.; López-Picazo González, JM.; García-Foncillas López, J.; Prósper Cardoso, F. "Stem cells and cancer: elucidating the origin of the cancer stem cell." Rev Med Univ Navarra 51 (2007): 14-17.